Nymox Pharma Files 6-K Regarding 20-F Annual Report
Ticker: NYMXF · Form: 6-K · Filed: Jul 18, 2024 · CIK: 1018735
| Field | Detail |
|---|---|
| Company | Nymox Pharmaceutical CORP (NYMXF) |
| Form Type | 6-K |
| Filed Date | Jul 18, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, annual-report
TL;DR
Nymox Pharma filed a 6-K about their 20-F annual report. Standard stuff.
AI Summary
Nymox Pharmaceutical Corporation announced on July 18, 2024, that it has issued a press release concerning its annual report on Form 20-F. This announcement is being furnished as part of a Form 6-K filing with the SEC.
Why It Matters
This filing provides an update on Nymox's regulatory reporting status, which is important for investors to track compliance and financial disclosures.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of an annual report announcement and does not contain new financial or operational information that would significantly alter risk.
Key Players & Entities
- Nymox Pharmaceutical Corporation (company) — Registrant
- July 18, 2024 (date) — Announcement Date
- Form 20-F (document) — Annual Report Form
- Form 6-K (document) — Current Report Form
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to furnish a press release regarding Nymox Pharmaceutical Corporation's annual report on Form 20-F.
When was the press release concerning the annual report issued?
The press release was issued on July 18, 2024.
Is the information in the press release considered 'filed' under Section 18 of the Securities Exchange Act?
No, the press release furnished as Exhibit 99.1 is not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act.
Does Nymox Pharmaceutical Corporation file annual reports under Form 20-F or Form 40-F?
Nymox Pharmaceutical Corporation files annual reports under cover of Form 20-F.
What is the principal executive office address of Nymox Pharmaceutical Corporation?
The principal executive office address is Bay & Deveaux Streets, Nassau, The Bahamas.
Filing Stats: 236 words · 1 min read · ~1 pages · Grade level 13.4 · Accepted 2024-07-18 15:36:48
Filing Documents
- nymox_6k.htm (6-K) — 11KB
- nymox_ex991.htm (EX-99.1) — 8KB
- nymox_ex991img3.jpg (GRAPHIC) — 4KB
- nymox_ex991img4.jpg (GRAPHIC) — 4KB
- 0001640334-24-001139.txt ( ) — 33KB
From the Filing
nymox_6k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2024 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant's name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F. Form 20-F Form 40-F Changes in Registrant's Certifying Accountants (a) Dismissal of Independent Registered Public Accounting Firm On July 18, 2024, Nymox Pharmaceutical Corporation (the "Company") issued a press release regarding the Company's annual report on Form 20-F. This press release is furnished as Exhibit 99.1 to this report on Form 6-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. 2 EXHIBIT INDEX Exhibit No. Description 99.1 Press Release of Nymox Pharmaceutical Corporation, dated July 18, 2024 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 18, 2024 NYMOX PHARMACEUTICAL CORPORATION By: /s/ Paul Averback Name: Paul Averback Title: President and Chief Executive Officer 4